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Abstract
Background: In Spain, more than 85% of coronary heart disease deaths occur in adults older than
65 years. However, coronary heart disease incidence and mortality in the Spanish elderly have been
poorly described. The aim of this study is to estimate the ten-year incidence and mortality rates of
myocardial infarction in a population-based large cohort of Spanish elders.
Methods: A population-based cohort of 3729 people older than 64 years old, free of previous
myocardial infarction, was established in 1995 in three geographical areas of Spain. Any case of fatal
and non-fatal myocardial infarction was investigated until December 2004 using the "cold pursuit
method", previously used and validated by the the WHO-MONICA project.
Results:  Men showed a significantly (p < 0.001) higher cumulative incidence of myocardial
infarction (7.2%; 95%CI: 5.94-8.54) than women (3.8%; 95%CI: 3.06-4.74). Although cumulative
incidence increased with age (p < 0.05), gender-differences tended to narrow. Adjusted incidence
rates were higher in men (957 per 100 000 person-years) than in women (546 per 100 000 person-
years) (p < 0.001) and increased with age (p < 0.001). The increase was progressive in women but
not in men. Adjusted mortality rates were also higher in men than in women (p < 0.001), being
three times higher in the age group of ≥ 85 years old than in the age group of 65-74 years old (p <
0.001).
Conclusion: Incidence of fatal and non-fatal myocardial infarction is high in the Spanish elderly
population. Men show higher rates than women, but gender differences diminish with age.
Background
Coronary heart disease (CHD) is the main cause of death
in the industrialized countries[1], and myocardial infarc-
tion (MI) the most dominant manifestation of the dis-
ease. In Spain, 11.2% of deaths in males and 9.6% in
females were related to CHD in 2005, and more than 85%
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of annual CHD deaths occur in subjects older than 65
years[2] Although CHD mortality has declined steadily
both in men and women[3], it still remains as one of the
most frequent causes of mortality[4]
Incidence studies conducted in Spain indicate that CHD is
a frequent disease in the general population, with rates in
order of 200 new myocardial infarctions per 100,000
men-year and 50 per 100,000 women-year respectively[5]
The higher incidence can be observed in the eldest age
group. In Spain more than 58% of hospital discharges
with the diagnosis of cardiovascular disease are over 65
years and 63% of MI patients admitted to hospitals are
over this age[6]. Although higher rates are observed over
the age of 65[2], most epidemiological studies still focus
on the middle-aged adult population, with scarce repre-
sentation of the elderly[7]. In fact, age for inclusion used
to be limited to 65 years[8] and few studies include sub-
jects older than 74 years[9]. The impact of striking demo-
graphic changes in the Spanish elderly population, with
an increase of ten million elders during the last decade,
and its effect on CHD incidence and mortality needs to be
evaluated.
The aim of this paper is to estimate the age- and sex- spe-
cific incidence and mortality rates of MI in a cohort of
Spanish elders during 10 years of follow-up (1995-2004).
Methods
The EPICARDIAN project is a multicenter, population-
based, epidemiological cohort study about cardiovascular
diseases in the elderly population of three Spanish areas:
Lista district (Madrid city); Arévalo county (Avila); and
Begonte county (Lugo). In the urban district of Lista
(Madrid city), where the number of registered elders was
large (>25.000), we selected an age- and sex- stratified ran-
dom sample of the population. In the other two study
sites (Lugo and Arévalo), all registered elders were invited
to the baseline examination. The response rate of the ini-
tial cohort selection was 85%. Study design and methods
have been previously published[10,11]
Population and design of the study
The original cohort was composed of 3729 subjects older
than 65 years old free of previous MI. All participants were
followed until the occurrence of the first MI, until death or
until 31/12/2004 if alive. Study design, response rates and
follow-up information are shown in figure 1.
Field study procedures
The fieldwork was developed into two phases. First phase
included a home standard examination, consisting of an
interview, physical examination and laboratory tests, in
which information on newly developed cardiovascular
disease was obtained. Registered nurses were trained and
certified in performing the interview. The interview
included questionnaires adapted and validated in Spanish
from the MONICA project[12] and the Rose question-
naire on chest pain and dysnea[13]. In 1998 and 2004 this
standard examination was repeated using the same con-
tact procedures and methods than in the baseline (1995).
The second phase pertained to the confirmation of CHD
events in those individuals who answered affirmatively
the questions about coronary disease or angina in the first
phase. We used the so called "cold pursuit method" previ-
ously used and validated by the MONICA Project, and
modified and adapted in Spain by the REGICOR and
IBERICA projects[14,15]. In the "cold pursuit method"
cases are identified and registered through their discharge.
We modified it for pin-pointing and investigating inci-
dent cases, employing all of the hospital and primary care
clinical records for confirming the cardiovascular event.
Causes and dates of death of the deceased individuals in
the cohort were also confirmed through the Spanish
National Death Index.
Cardiovascular information was requested for all poten-
tial lost cases using secondary sources (clinic history,
interviewing assigned general practitioner, National Insti-
tute of Statistics, mails, and phone calls to the subject or
relatives).
Definition of myocardial infarction (MI)
Criterion was based on symptoms, enzyme changes, ECG
changes (Minnesota code)[16,17] and post-mortem find-
ings defined in the WHO coding criteria[18] and the
validity of the diagnosis was ensured by intra-observer
studies[19]
We considered Definite MI in those subjects who pre-
sented a definite ECG or typical/atypical symptoms,
together with a probable ECG and abnormal enzymes, or
those with typical symptoms, abnormal enzymes and
ischemic ECG.
Possible MI or Coronary Death was considered in those
alive subjects with typical symptoms where enzymes and
ECG did not allow classification into the definite category,
with no evidence of other diagnosis; or death patients
with no clear evidence of other cause of death. A Coronary
event was considered fatal if death occurred within
28 days of the onset. Under the epigraph "sudden death"
were included those subjects who died within the first 24
hours from the onset of clinical symptoms, deaths with-
out witness or when the subject was well in the previous
24 hours.
No MI was set in alive patients when the symptoms and
diagnostic tests combinations did not allow its classifica-
tion into the possible MI or when the event could beBMC Public Health 2009, 9:360 http://www.biomedcentral.com/1471-2458/9/360
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explained by means of other causes. In fatal events, MI
was rejected when death was related to different clinical
diagnosis or autopsy.
Ischaemic cardiac event includes all coronary events that
satisfy the criteria for non-fatal definite myocardial infarc-
tion or coronary death (fatal definite infarction, fatal pos-
sible infarction, or sudden death).
Statistical methods
Basic statistics of centralization (mean, median and its
standard deviation and distribution values) were used to
describe continuous variables. For the calculation of rates
and proportions, the distribution of relative frequencies
with confidence intervals at 95% by the Poisson approxi-
mated method were used.
To compare proportions the Pearson chi squared test or
the chi squared for linear trend for several categories were
used. Any value p < 0.05 was considered statistically sig-
nificant. The Kaplan-Meier actuarial method was used in
order to estimate the cohort survival and crude incidence
rates. Crude incidence rates were standardized for age at
baseline by the direct method, using as reference the Euro-
pean population distribution in 2006 as reference[20]
Cumulative incidence is calculated by the number of new
cases during the period of study divided by the number of
subjects at risk in the population at the beginning of the
study. Mortality is the number of deaths in the popula-
tion. Incidence rate is the number of first fatal and/or non-
fatal events per unit of person-time at risk. Mortality rate
is the number of fatal events per unit of person-time at
risk. Case fatality is the proportion of fatal MI in all MI.
Incidence and mortality rates are presented per 100,000
person-years, and case-fatality as a percentage by age at
baseline and sex groups for the ten-year follow-up.
Our research is in compliance with the Helsinki Declara-
tion http://www.wma.net/e/policy/b3.htm. All partici-
pants signed a informed consent at the beginning of the
study. The study protocol was approved by the ethics com-
mittee of the Hospital Universitario de la Princesa,
Madrid.
Results
General characteristics of the initial cohort (n = 3729) and
distribution of major cardiovascular risk factors are
described in table 1. The initial response rate was 85%.
There were 1297 (34.8%) subjects from Lista, 989
(26.5%) from Begonte, and 1443 (38.7%) from Arévalo.
The mean age of the cohort at baseline was 74.2 ± 0.4
years (74.43 in women and 73.82 in men). The initial
cohort of 3729 subjects accounted for a total 27661 per-
sons-year of follow-up. Median follow-up for the entire
cohort was 7.4 years.
In total, 305 CHD events occurred in the entire cohort
during the 10-year follow-up period. There were 95 cases
of non-fatal definite MI; 101 of fatal definite MI; 51 of
possible MI, and 58 of sudden death (table 2). Men
showed a higher and significant cumulative incidence of
ischemic events (p < 0.001); definite MI (p < 0.001); fatal
(p < 0.05) and non-fatal MI (p < 0.05); and sudden death
(p < 0.05) than women. When we analyzed cumulative
incidence by age we observed an increased incidence of
fatal MI with age (p < 0.001) but incidence of non-fatal
definite MI did not show a significant increase. The anal-
ysis by age, considering the age at the beginning of the
study, also showed that men had higher non-fatal cardio-
vascular risk at earlier ages whereas women described a
progressive increase in all cardiovascular risk.
Figure 2 graphically depicts sex and age-related differences
in incidence rates (first event) of different acute myocar-
dial infarction diagnostic categories. Rates progressively
increase in women but not in men. Men showed similar
incidence rates at 65-74 and 75-84 age-groups. Males and
females older than 85 years showed the highest incidence
rates. Age- standardized incidence rate (per 100 000 per-
son-years) for first definite (fatal and non fatal) MI was
Flow-chart EPICARDIAN study (1995-2004) Figure 1
Flow-chart EPICARDIAN study (1995-2004). Coro-
nary heart disease (CHD).
1998
STUDY POPULATION FLOW-CHART:  
Epicardian Study 
RANDOM SAMPLE 
(>64 years) 
             N = 5314 1994
1995
-Total No. of CHD cases in 10 years: 305 
-Total alive subjects not interviewed (not localized or rejected) in 10-year follow-up: 31/3729 (16.9%)
      INTERVIEWED  
           N = 4207 
FREE OF PREVIOUS MI AT 
BASELINE   n= 3729 
Not localized, death or 
rejected: 1107 (20.1%) 
MI Prevalent cases 
(excluded): 478 (11.4%) 
Deaths 1995-98: 361 
1998  INTERVIEWED 
Not localized or rejected 2nd. 
interview: 187 of 3368 (5.5%)       
n= 3181 of 3368 alive 
(94.4%) 
 INTERVIEWED 
 n= 1849 of 2480 alive 
(75%) 
Deaths 1998-2004: 888 
2004 Not localized or rejected 3rd. 
interview: 444 of 2480 (17.9%)BMC Public Health 2009, 9:360 http://www.biomedcentral.com/1471-2458/9/360
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greater in men (957; 95%CI: 899-1019) than in women
(546; 95%CI: 514-606) (p < 0.001).
Among the 3729 subjects, 1249 died for any reason dur-
ing the 10 years of follow-up, which represents a total
mortality proportion of 33.5%. The cumulative mortality
for CHD, MI or sudden death, was 4.3% (95%CI: 3.6-
5.0), higher in men 5.7% (95%CI: 4.6-7.0) than in
women 3.2% (95%CI: 2.5-4.0) (p < 0.001); (Table 2).
Finally, MI as definite cause of death was confirmed in 58
subjects, which resulted in a specific MI mortality of 2.7%
(95%CI: 2.2-3.3). MI mortality rate was also higher in
males than in women and particularly among the eldest
groups (p < 0.001). Case fatality also increases with age in
both genders (p < 0.05) and was higher in men than in
women (p < 0.01) (table 3).
Crude CHD mortality rate was 575 per 100 000 person
years with higher figures in men (770 per 100 000 person-
years) than in women (428 per 100 000 person-years) (p
< 0.001). MI mortality rate was 365 (95%CI: 329-404) per
100,000 person- years, greater in men (491; 95%CI: 449-
536) than in women (271; 95%CI: 240-305) (p < 0.001).
MI adjusted-mortality rates (table 4) were also higher in
men (484; 95%CI 442-529) than in women (293; 95%CI
260-329) (p < 0.001). Population aged ≥ 85 years old at
baseline reached the highest value with 815 cases per
100.000 person-years, twice compared to 75-84 years old
(388 per 100.000 person-years), and three times com-
pared to 65-74 years old (281 per 100.000 person-years)
(p < 0.001).
Discussion
This study confirms the magnitude of the impact of MI in
the Spanish elderly population, substantially higher than
in those younger than 65 years of age[21,22] Elderly men
show higher MI incidence and mortality rates than
women, particularly at earlier ages (65-74 years old), but
these gender differences tend to narrow as they get older.
During the last few years, several epidemiological studies
have been initiated in Spain to estimate the MI incidence
and mortality. However, they [14,15,23] were limited to
middle-age subjects and included scarce number of partic-
ipants from the eldest groups of age. EPICARDIAN study
is the first population-based cohort study in the elderly in
Spain, with individual follow-up of study participants for
a long period of time (10 years of follow-up). A pilot
study reporting the study methods in detail and prelimi-
nary results in one (Madrid) of the three areas of the main
study have been published recently (11). This cohort has
similar socio-demographic characteristics and show a
similar cardiovascular risk profile than those described in
the scarce the scarce studies carried out in ancients in
Spain. There is a Spanish registry, the REGICOR-65
plus[24], that provides information on MI rates in the eld-
erly population of Girona, but the methodology to detect
cases is different and only MI cases between 1996 and
1997 were registered, and then it may not represent so
accurately the real increase in individual risk as the popu-
lation get older.
In order to compare our results with other studies we
adopted previously used and validated international epi-
demiological procedures and criteria for the identification
and classification of MI[25] Nevertheless, almost all epi-
demiological studies share similar limitations when trying
to identify cardiac events. One important limitation is the
difficulty to identify unrecognized MI, which has been
described to reach a particularly high proportion in the
elderly and postmenopausal women[26] However, we
tried to minimize this potential underestimation using
multiple specific strategies such as reviewing clinical
Table 1: Demographic characteristics and distribution of major cardiovascular risk factors in the EPICARDIAN study population at 
baseline (year 1995).
Cardiovascular risk factors Men
n (%)
n = 1592
Women
n (%)
n = 2137
Both
n (%)
n = 3729
Age group 65-74 975 (61.2) 1228 (57.4) 2203 (59.0)
75-84 487 (30.6) 692 (32.4) 1179 (31.7)
> = 85 130 (8.2) 217 (10.2) 347 (9.3)
Hypertension 969 (60,8) 1497 (70,0) 2466 (66,1)
Hypercholesterolemia 347 (21,8) 709 (33,2) 1056 (28,3)
Diabetes 170 (10,7) 254(11,9) 424 (11,4)
Obesity 302 (18,9) 605 (28,3) 907 (24,3)
Smoking 340 (21,4) 69 (3,2) 409 (10,9)
Number of cases and their corresponding percentages (%)
Hypertension: SBP = 140 mmHg or DBP = 90 mmHg or antihypertensive treatment.
Diabetes: venous glucose ≥ 126 mg/dl or antidiabetic treatment.
Hypercholesterolemia: Cholesterol ≥ 250 mg/dL or lipid lowering treatment
Obesity: Body Mass Index (BMI) ≥ 30 kg/m2.
Smoking: 1 cigarette per day or 5 per week during the last yearBMC Public Health 2009, 9:360 http://www.biomedcentral.com/1471-2458/9/360
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reports. Other particular limitation is the possible under-
estimation of ischemic events, especially during the third
period of follow-up (1998-2004), due to the elevated pro-
portion of not contacted subjects (n = 631; 17%). Never-
theless we used secondary sources of information in order
to detect possible cases of MI in all of these subjects. It
should be also emphasized that the diagnosis of MI was
not only based on the ECG, but also on the clinical symp-
toms and the results of laboratory testing (CK-MB eleva-
tions). One might always speculate that the application of
more recent diagnostic tools, such as troponin levels,
might have revealed a higher proportion of MI cases, as
has been estimated by other studies[27] A possible under-
estimation of the impact of MI in our population can also
be explained because of the exclusion of institutionalized
subjects and persons with evidence of relevant disabilities
and life threatening diseases.
Once these potential limitations are assumed, the inci-
dence of definite MI seems to be in accordance with other
studies carried out in Spain describing higher incidence
rates amongst the elderly than rates in middle age-adults.
This finding is of crucial importance since elderly people
are the fastest growing population segment in western
countries and, in consequence, demand for health
resources of diagnosis and treatment is bound to
increase[28] When comparing our results to those of the
REGICOR-65 plus study[24] we observed higher absolute
values in our study but both confirm an overall increase
with age, and higher risk in men than in women (table 4).
Table 2: Cumulative number of cases and risk by sex and age of different CHD diagnostic categories in 10 years of follow-up (1995-
2004).
CHD diagnostic
Categories
Males Females Total
(95%CI)
p
65-74 75-84 <85 All males
(95%CI)
65-74 75-84 <85 All females
(95%CI)
Non-fatal definite AMI No. of events 38 15 3 56 19 14 6 39 95
% 3.9 3.1 2.3 3.5 (2.6-4.5)
p = 0.53
1.5 2.0 2.8 1.8 (1.3-2.5)
p = 0.42
2.5 (2.1-3.1) <0.05
Possible AMI No. of events 15 8 2 25 10 12 4 26 51
% 1.5 1.6 1.5 1.6 (1.0-2.3)
p = 0.8
0.8 1.7 1.8 1.2 (0.8-1.7)
p = 0.142
1.4 (1.0-1.8) 0.05
Sudden death No. of events 13 14 6 33 2 19 4 25 58
% 1.3 2.9 4.6 2.1(1.4-2.9)
p < 0.05
0.2 2.7 1.8 1.2 (0.7-1.7)
p < 0.001
1.6 (1.2-2.0) <0.001
Fatal and non-fatal
definite AMI
No. of events 71 31 12 114 32 32 18 82 196
% 7.3 6.4 9.2 7.2(6.0-8.5)
p = 0.51
2.6 4.6 8.3 3.8(3.0-4.7)
p < 0.001
5.3 (4.6-6.0) <0.001
Ischemic event No. of events 99 53 20 172 44 63 26 133 305
% 10.2 10.9 15.4 10.8(9.3-12.3)
p = 0.2
3.6 9.1 12 6.2 (5.2-7.3)
p < 0.001
8.2 (7.3-9.1) <0.001
Possible and non-
fatal definite AMI
No. of events 53 23 5 81 29 26 10 65 146
% 5.4 4.7 3.8 5.1(4.0-6.2)
p = 0.67
2.4 3.8 4.6 3.0
p = 0.085
3.9 (3.3-4.6) 0.01
CI: Confidence Intervals. "p" represents differences by age and gender. Ischemic event includes all coronary events that
satisfy the criteria for non-fatal definite myocardial infarction or coronary death (fatal definite infarction,
fatal possible infarction, or sudden death)BMC Public Health 2009, 9:360 http://www.biomedcentral.com/1471-2458/9/360
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Crude rates by sex and age per 100.000 person-years of different acute myocardial infarction diagnostic categories Figure 2
Crude rates by sex and age per 100.000 person-years of different acute myocardial infarction diagnostic cate-
gories. Ischaemic event definition includes all coronary events that satisfy the criteria for non-fatal definite myocardial infarction 
or coronary death (fatal definite infarction, fatal possible infarction, or sudden death).
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Interestingly, in our study, the age-related increase was
progressive in women but not in men, and also in accord-
ance with that observed in other studies, in which a con-
centration of cases occurred in men between 65-74 years
in men[29] and over this age in women[15] The question
of whether males prematurely develops CHD because a
gender related genetic predisposition or whether their
occurrence is delayed in women because of a shorter expo-
sure to relevant cardiovascular risk factors arises. The rela-
tive higher increase of MI risk with age, observed in elderly
females, could be related to the higher burden of cardio-
vascular risk factors described in the postmenopausal
women (see table 1).
In the international context, the incidence rates in our
study are lower than other European[26,30] and Ameri-
can [31-33] cohort studies (table 4), but age- and sex- dis-
tributions are quite similar. This finding can be explained
by a real higher MI incidence in north-European and
American elderly populations, as it has been described for
middle-age adult population in the International MON-
ICA study. Since Spanish elders, as middle-aged adults,
show a high prevalence of cardiovascular risk factors[11],
the intriguing paradox of a low MI incidence and mortal-
ity in southern Europe despite the high cardiovascular risk
factor prevalence[34] is likely to hold in older ages.
Men showed a significantly higher CHD mortality com-
pared with that of women, but gender differences are less
evident when specific mortality rates (MI rates instead of
CHD rates) are considered. A recently published popula-
tion-based myocardial infarction (MI) register in persons
aged 75 to 99 years describes a CHD annual mortality dec-
lination among men by 3.5% and 1.0% in the group 75 to
99-years-old. Among women, it declined by 2.2% per year
in the 75- to 84-year-old age group but increased by 1.3%
per year in the 85- to 99-year-old age group. MI attack rate
did not change in men but increased significantly in
Table 3: Myocardial infarction case fatality by age at baseline and 
sex among participants. EPICARDIAN (1995-2004)
Gender Age Case fatality
(95%CI)
No. of events
Fatal MI/all MI
Men 65-74 38% (29-49) 33/86
75-84 41% (27-57) 16/39
>85 64% (38-86) 9-14
Women 65-74 31% (18-46) 13/42
75-84 41% (27-55) 18/44
>85 55% (33-74) 12-22
Total >65 41% (35-47) 101/247
Values represent proportion with fatal events within each group
All MI (Myocardial Infarctions): definite and possible
p for trends (age) <0.05; p (gender) <0.01
Table 4: Incidence rates and mortality rates for acute myocardial infarction (AMI) in different national and international studies 
carried out in the elderly.
All incidence rates All mortality rates
Study
Period of Study
(Reference No.)
Age
Group
Men Women Men Women
EPICARDIAN Study
REGICOR-65 plus (24)*
65-74 981(921-1044)
599(528-670)
351(316-389)
166(131-202)
456(416-499)
220(177-263)
142(120-167)
55(35-75)
75-84 858(802-917)
972(840-1105)
623(576-673)
409(338-481)
442(402-485)
570(468-672)
350(315-388)
223(170-276)
>85 1244(1177-1314)
1071(791-1351)
1118(1054-185)
671(307-836)
933(875-994)
740(506-973)
745(693-800)
426(295-558)
EPICARDIAN Study**
1994-2004
>65 957(898-1018) 546(502-594) 484(442-529) 293(260-329)
Oxford Study
1994-95 (30)
65-79 1585 868 826 478
Rotterdam Study
1990-2000 (26)
>55 840(660-1020)1
420(280-550)2
310(230-390)1
360(2.60-450)2
Bronx Aging Study
1981-89 (31)
>75 4700 (total) 3900 (total)
Cardiovascular Health
Study 1989-90 (32)
>65 2070 790
Framingham Heart
Study1960-1999 (33)
65-74 1800 800
75-84 2700 1400
**Age- standardization by the European Standard Population (Eurostat 2006) as reference
*New and recurrent cases
1 recognized myocardial infarction
2 unrecognized myocardial infarction
Rates per 100,000 person-years (95% Confidence interval)BMC Public Health 2009, 9:360 http://www.biomedcentral.com/1471-2458/9/360
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women aged 85 to 99 years. [34] Previous research indi-
cates significant age-associated differences in clinical char-
acteristics in elderly patients with AMI, which account for
some of the age-associated differences in mortality. Older
age is associated with a higher prevalence of co-morbid
conditions, atypical AMI presentation, non-diagnostic
electrocardiograms, complications and mortality and
with significant cardiovascular structural and physiologic
changes that might predispose patients to adverse out-
comes, including abnormalities of left ventricular diasto-
lic function, decrease in systemic vascular compliance,
increased coagulation factors, and altered neurohormonal
and autonomic influences. [35]
Lastly, increased fatality with age may be related to lower
effectiveness of life-saving treatments, lower hospitaliza-
tion rates, lower use of diagnostic and therapeutics proce-
dures, longer delay between onset of symptoms and
admission to the emergency room and more co-morbidity
in the elderly [36-38].
Conclusion
In summary, we conclude that incidence of fatal and non-
fatal MI is high in the Spanish elderly population. Overall
MI impact remains greater in men compared to women
but gender differences tend to narrow as male and female
get older. The importance of including older patients in
strategies to the prevention and management of MI
should be considered
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